A Phase I Study of Pomalidomide in Patients with Recurrent or Persistent Primary Central Nervous System Lymphoma or Primary Vitreoretinal Lymphoma

Full Title

Phase I Trial of Pomalidomide for Patients with Relapsed/Refractory Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma


Pomalidomide is an anticancer drug that modulates immune cells and inhibits the growth of the blood vessels that cancers need to grow and spread. When given with dexamethasone, pomalidomide helps to kill cancer cells.

In this study, researchers want to find the highest dose of pomalidomide that can be given safely with dexamethasone to patients with primary central nervous system lymphoma (PCNSL) or primary vitreoretinal lymphoma (PVRL) that has come back after therapy or has continued to grow despite other treatments. Pomalidomide has shown activity against lymphoma in laboratory studies and penetrates well into the brain, making it a promising drug to treat PCNSL and PVRL.

Pomalidomide is approved for the treatment of a bone marrow cancer called multiple myeloma, but its use in this study is investigational. It is a capsule that is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have PCNSL or PVRL that has come back after therapy or has continued to grow despite other treatments.
  • At least 3 weeks must pass between completion of prior chemotherapy and entry into the study.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Christian Grommes at 212-639-4058.





Disease Status

Relapsed or Refractory